Fonte: Fortune
Daraxonrasib nearly doubled pancreatic cancer survival to 13.2 months — but the IRA's "Pill Penalty" threatens the system that produced it.
Ler na Fonte
Notícias Relacionadas
Lista de Notícias
When 10,000 doctors stood up and cheered for a cancer drug — America’s innovation machine made it possible
America
Fortune
há 10h
